Expect a negative near-term reaction in AZN and partner Ionis (not directly named in filing) as the ATTR-CM program is now at risk. The monotherapy subgroup signal provides a potential path forward, but the lack of benefit on top of stabiliser is a significant headwind. Monitor the ESC Congress in August for further data and regulatory strategy updates.
Price Chart
Executive Summary
AstraZeneca announced that the CARDIO-TTRansform Phase III trial for Wainua (eplontersen) in transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) did not meet the primary composite endpoint of CV mortality and recurrent CV events versus placebo. The drug was generally well tolerated, but adding it to standard of care including a majority on a stabiliser showed no statistically significant benefit. A prespecified monotherapy subgroup showed nominally significant fewer events, while no effect was seen in patients on stabiliser at baseline. The failure is a setback for AZN's pipeline in a large indication, but the stock impact may be moderated by the company's diversified portfolio and the monotherapy signal.
Key Facts
- CARDIO-TTRansform Phase III trial did not meet the primary efficacy endpoint of composite CV mortality and recurrent CV events up to 140 weeks.
- Trial enrolled 1,432 participants across 130 sites in 20 countries, randomised 1:1 to eplontersen 45 mg or placebo.
- 57% of patients in each arm received a stabiliser at baseline; a further 24% in each arm initiated a stabiliser during the trial.
- Prespecified monotherapy subgroup showed nominally significant fewer primary composite events; no treatment effect observed in patients on stabiliser at baseline.
- Full data analysis will be shared at the European Society of Cardiology Congress in August 2026.
Financial Impact
The failure reduces the probability of approval for the ATTR-CM indication, which could have been a multibillion-dollar opportunity. No specific financial figures from the filing.
Risk Factors
- Negative trial outcome could lead to write-down of asset value and reduced pipeline confidence.
- Nominal significance in monotherapy subgroup may not be sufficient for regulatory approval without additional trials.
- Competitors with approved stabilisers (tafamidis) maintain market dominance.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001654954-26-006554 |
| Document: 0001654954-26-006554-index-headers.html | 0001654954-26-006554 |
| Document: 0001654954-26-006554-index.html | 0001654954-26-006554 |
| Document: 0001654954-26-006554.txt | 0001654954-26-006554 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | 6-K | $161.85 $168.37 | ▲ +4.03% | ▲ +1.90% | $157.02 (−2.98%) |
Sep 14, 2026 18d ago | 6-K | $163.78 $168.10 | ▼ −2.64% | ▼ −2.53% | $157.02 (+4.13%) |
Sep 8, 2026 24d ago | 6-K | $160.04 $161.85 | ▲ +1.13% | ▲ +2.25% | $157.02 (−1.89%) |
Sep 1, 2026 4w ago | 6-K | $162.22 $156.94 | ▼ −3.25% | ▼ −3.33% | $157.02 (−3.20%) |
Sep 1, 2026 4w ago | 6-K | $162.22 $156.94 | ▼ −3.25% | ▼ −3.33% | $157.02 (−3.20%) |
Sep 1, 2026 4w ago | 6-K | $162.47 $156.94 | ▼ −3.40% | ▼ −3.49% | $157.02 (−3.35%) |
Sep 1, 2026 4w ago | 6-K | $162.22 $156.94 | ▼ −3.25% | ▼ −3.33% | $157.02 (−3.20%) |
Sep 1, 2026 4w ago | 6-K | $162.22 $156.94 | ▼ −3.25% | ▼ −3.33% | $157.02 (−3.20%) |
Sep 1, 2026 4w ago | 6-K | $162.47 $156.94 | ▼ −3.40% | ▼ −3.49% | $157.02 (−3.35%) |
Aug 31, 2026 4w ago | Court Ruling | $162.13 $159.95 | ▲ +1.34% | ▲ +1.20% | $157.02 (+3.15%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access